Reversal of earlier rejection by Nice of abemaciclib – known as Verzenios – is welcomed by campaigners
A breast cancer drug that was rejected for routine NHS use in England earlier this year has now been recommended by health officials after a discount was agreed with the manufacturer.
The decision has been described as “fantastic news for thousands of women” by a charity, which said the introduction of this drug would give “precious extra months” for those who are very unwell.
